Speed Is Not an Outcome. Speed Is a Choice.
Speed is not what happens when everything goes perfectly. Speed is what happens when you deliberately architect your organisation to prioritize movement over perfection.
The fastest launching pharmaceutical companies are not faster because their people work harder. They are faster because their operating model is built for speed.
Three Operating Model Choices That Drive Speed
Building speed into your launch means making three deliberate architecture decisions:
1. Compressed Decision Cycles
Every approval layer adds latency. Most pharmaceutical launches have 4-6 approval layers from execution to P&L owner. That means 18-36 days of latency before a decision gets made.
In pharma, 18 days is forever.
Speed means cutting ruthlessly:
- Make decisions at the lowest possible level
- Eliminate approval layers where possible
- Use escalation criteria, not approval gates
- Define decision authority upfront, not during crises
The operating model should assume that decisions happen in 24-48 hours, not 2-4 weeks.
2. Tighter Cross-Functional Coordination
Cross-functional coordination is not a meeting. It is how you structure the team.
Instead of separate Commercial, Medical, and Regulatory teams coordinating through steering committees, embed functions together in temporary launch pods.
- Commercial pod: Sales, Market Access, Customer Insights
- Clinical pod: Medical Affairs, Real-World Evidence, HCP Engagement
- Regulatory pod: Regulatory Affairs, Post-Market Compliance, Safety Reporting
Each pod meets daily. They solve problems together. No hand-offs.
3. Embedded Execution Ownership
The person forming strategy is the person in the room during execution. No hand-offs. No translation.
This is not agile theatre. It is operating discipline:
- One senior voice owns the launch strategy
- That person controls the budget
- That person is accountable for the outcome
- That person is present during execution, not just in planning meetings
This removes ambiguity. It accelerates decision-making. It forces alignment.
What This Looks Like in Practice
A speed-optimized launch operating model has these characteristics:
Pre-Launch (Month -12 to 0)
- One senior leader owns the launch strategy, not a committee
- Strategy is frozen 6 months before launch (not still being refined 3 months in)
- Budget authority is clear and centralized, not split across functions
- The launch team is co-located (physically or virtually) to enable daily coordination
Launch Phase (Month 0 to 12)
- Daily stand-ups identify and resolve blockers in 24 hours
- Decisions flow upward only when escalation criteria are met
- All major decisions are made by the launch leader, not committees
- Budget flexibility allows reallocation within 72 hours without approval
Post-Launch (Month 12+)
- Performance data is reviewed weekly, not quarterly
- Mid-course corrections are made in real time, not planned for next quarter
- Capability is transitioned to permanent teams with 30-day overlap, not 6-month phase-out
Why This Works
Speed is not about working longer hours. It is about reducing latency between decision and execution.
Traditional pharma orgs have latency built in. Speed-optimized orgs have latency designed out.
The operating model is where speed lives.
The Competitive Advantage
In a competitive indication, time to peak is often measured in weeks, not months. A 4-week advantage in execution can mean 15-20% market share difference in Year 1.
That is not a small advantage. That is a business-defining advantage.
Build your next launch operating model for speed. Every decision you make should reduce latency, not add it. Every layer you add should have to justify why it is faster than removing it.
Speed is a choice. Choose it.
